E-LIB Suche - Ergebnisse für: Kubitza, A.

1

The complete bioavailability of asundexian is unaffected by..:

Kanefendt, F ; Brase, C ; Unger, S.
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

2

First‐in‐man–proof of concept study with molidustat: a nove..:

Böttcher, M. ; Lentini, S. ; Arens, E. R....
British Journal of Clinical Pharmacology. 84 (2018) 7 - p. 1557-1565 , 2018

Link: https://doi.org/10.1111/..

3

Dissociation between the pharmacokinetics and pharmacodynam..:

Kreutz, R. ; Persson, P.B. ; Kubitza, D....
Journal of Thrombosis and Haemostasis. 15 (2017) 10 - p. 2017-2028 , 2017

Link: https://doi.org/10.1111/..

4

Comparison of three-factor and four-factor prothrombin comp..:

Levi, M. ; Moore, K. T. ; Castillejos, C. F....
Journal of Thrombosis and Haemostasis. 12 (2014) 9 - p. 1428-1436 , 2014

Link: https://doi.org/10.1111/..

5

Absence of Clinically Relevant Interactions between Rivarox..:

Kubitza, D ; Becka, M ; Roth, A.
Journal of International Medical Research. 40 (2012) 5 - p. 1688-1707 , 2012

Link: https://doi.org/10.1177/..

6

Prospective randomized comparison of conventional instrumen..:

Böhm, D. ; Kubitza, A. ; Lebrecht, A....
European Journal of Surgical Oncology (EJSO). 38 (2012) 2 - p. 118-124 , 2012

Link: https://doi.org/10.1016/..

7

The in vitro anticoagulant effect of rivaroxaban in childre:

Attard, C. ; Monagle, P. ; Kubitza, D..
Thrombosis Research. 130 (2012) 5 - p. 804-807 , 2012

Link: https://doi.org/10.1016/..

8

Moxifloxacin: Translating preclinical findings into QT-prol..:

Hoffmann, M. ; Himmel, H.M. ; Kubitza, D.
Journal of Pharmacological and Toxicological Methods. 58 (2008) 2 - p. 158 , 2008

Link: https://doi.org/10.1016/..

9

The influence of continuous venovenous haemodialysis on the..:

Stass, H. ; Bührmann, S. ; Mitchell, A....
British Journal of Clinical Pharmacology. 64 (2007) 6 - p. 745-749 , 2007

Link: https://doi.org/10.1111/..

10

Safety, pharmacodynamics, and pharmacokinetics of single do..:

KUBITZA, D ; BECKA, M ; VOITH, B..
Clinical Pharmacology & Therapeutics. 78 (2005) 4 - p. 412-421 , 2005

Link: https://doi.org/10.1016/..

11

Influence of activated charcoal on the pharmacokinetics of ..:

Stass, H. ; Kubitza, D. ; Möller, J.‐G..
British Journal of Clinical Pharmacology. 59 (2005) 5 - p. 536-541 , 2005

Link: https://doi.org/10.1111/..

12

Pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolo..:

Stass, H. ; Kubitza, D. ; Halabi, A..
British Journal of Clinical Pharmacology. 53 (2002) 3 - p. 232-237 , 2002

Link: https://doi.org/10.1046/..

13

Profile of Moxifloxacin Drug Interactions:

Stass, H. ; Kubitza, D.
Clinical Infectious Diseases. 32 (2001) Supplement_1 - p. S47-S50 , 2001

Link: https://doi.org/10.1086/..

14

Profile of Moxifloxacin Drug Interactions:

H. Stass ; D. Kubitza
Clinical Infectious Diseases. 32 (2001) - p. S47-S50 , 2001

Link: https://www.jstor.org/st..

15

Interaction Profile of Moxifloxacin:

Stass, H ; Kubitza, D
Drugs. 58 (1999) Supplement 2 - p. 235-236 , 1999

Link: https://doi.org/10.2165/..